Abstract
Alois Alzheimer identified first abnormal deformation in the brain of diseased people with mental disorder. The disorder is clinically characterized by a progression from episodic memory problems to a slow global decline of cognitive function, ending with the final stage when patients become bedridden and death occurs on average 9 years after diagnosis. The current standard of care does not cover the approved and effective treatment of both cognitive and non-cognitive symptoms. Tremendous effort was put in investigation of the disease development. The uncovered molecular mechanism shed light on aspartic proteases, the smallest protease class with about 15 members in the human genome. Here we summarise the most important structure-based developments on one of the most popular aspartic protease target BACE1.
Keywords: Alzheimer disease, BACE1, structure-based drug design, virtual screening.
Current Pharmaceutical Design
Title:Structure-Based β-Secretase (BACE1) Inhibitors
Volume: 20 Issue: 20
Author(s): Timea Polgar and Gyorgy M. Keseru
Affiliation:
Keywords: Alzheimer disease, BACE1, structure-based drug design, virtual screening.
Abstract: Alois Alzheimer identified first abnormal deformation in the brain of diseased people with mental disorder. The disorder is clinically characterized by a progression from episodic memory problems to a slow global decline of cognitive function, ending with the final stage when patients become bedridden and death occurs on average 9 years after diagnosis. The current standard of care does not cover the approved and effective treatment of both cognitive and non-cognitive symptoms. Tremendous effort was put in investigation of the disease development. The uncovered molecular mechanism shed light on aspartic proteases, the smallest protease class with about 15 members in the human genome. Here we summarise the most important structure-based developments on one of the most popular aspartic protease target BACE1.
Export Options
About this article
Cite this article as:
Polgar Timea and Keseru M. Gyorgy, Structure-Based β-Secretase (BACE1) Inhibitors, Current Pharmaceutical Design 2014; 20 (20) . https://dx.doi.org/10.2174/13816128113199990607
DOI https://dx.doi.org/10.2174/13816128113199990607 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amyloid Beta Protein and Tau in Cerebrospinal Fluid and Plasma as Biomarkers for Dementia: A Review of Recent Literature
Current Clinical Pharmacology Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies
Current Medicinal Chemistry Ivabradine: A Current Overview
Current Clinical Pharmacology Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Abnormal Saccadic Intrusions with Alzheimer's Disease in Darkness
Current Alzheimer Research Chirality - A New Era of Therapeutics
Mini-Reviews in Medicinal Chemistry Prognostic Role of Sub-Clinical Hypothyroidism in Chronic Heart Failure Outpatients
Current Pharmaceutical Design Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Current Pharmaceutical Design Planum Temporale Analysis Via a New Volumetric Method in Autoptic Brains of Demented and Psychotic Patients
Current Alzheimer Research Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Current Topics in Medicinal Chemistry Genetic Association of CUGBP2 and DNMBP with Alzheimer’ s Disease in the Chinese Han Population
Current Alzheimer Research Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry A Coadunation of Biological and Mathematical Perspectives on the Pandemic COVID-19: A Review
Coronaviruses DNMT3B Promoter Polymorphisms and Risk of Late Onset Alzheimer’s Disease
Current Alzheimer Research The Interplay Between Depression and Parkinson´s Disease: Learning the Link Through Ca<sup>2+</sup>/cAMP Signaling
Current Protein & Peptide Science Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Current Alzheimer Research Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Cholesterol and LDL Relate to Neuritic Plaques and to APOE4 Presence but Not to Neurofibrillary Tangles
Current Alzheimer Research